Literature DB >> 9633897

Differential constitutive activation between STAT-related proteins and MAP kinase in primary acute myelogenous leukaemia.

F Hayakawa1, M Towatari, H Iida, H Wakao, H Kiyoi, T Naoe, H Saito.   

Abstract

Many cytokines and growth factors stimulate multiple signal transduction pathways essential for proliferation in human acute leukaemia cells, including a mitogen-activated protein (MAP) kinase pathway and a Janus kinase (JAK)-STAT (signal transducers and activators of transcription) pathway. We have previously shown constitutive activation of MAP kinase in approximately 50% of acute myelogenous leukaemia (AML) samples. Recently, STAT proteins have been reported to be constitutively activated in 10-20% of AML cases. STAT3 and STAT5 are the main STAT proteins activated in haemopoietic progenitors in response to cytokines such as IL-3, GM-CSF, erythropoietin and thrombopoietin. Although the possibility of STAT1 protein as a substrate for MAP kinase at a serine residue has been suggested, the cross-talk between STATs and MAP kinase pathways in vivo, especially in leukaemia cells, remains unknown. We examined the phosphorylation of STAT 3 and STAT 5 at the tyrosine residues in AML samples in which MAP kinase activity had already been found. 40/50 primary AML cases (80%) exhibited constitutive tyrosine phosphorylation of STAT5. Electrophoretic mobility shift assay showed DNA binding activity of STAT5 correlated with tyrosine phosphorylation of STAT5. Similarly, with respect to STAT3, 17/23 cases examined (74%) showed constitutive tyrosine phosphorylation of STAT3. In addition, we examined the tyrosyl-phosphorylation of STAT5 isoforms, STAT5A and STAT5B, in 20 AML cases, and found selective STAT5B phosphorylation in the absence of STAT5A phosphorylation in three cases. Furthermore, in certain AML cases, constitutive activation of MAP kinase and STAT proteins occurred independently. No significant correlation of MAP kinase activation was observed with either tyrosine phosphorylation of STAT3/STAT5 or positive DNA binding of STAT proteins. These results suggest that constitutive activation of STAT proteins occurs commonly and that the causes of constitutive activation of these two major cascades are heterogeneous in AML.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633897     DOI: 10.1046/j.1365-2141.1998.00720.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  13 in total

1.  RNAi screening of the tyrosine kinome identifies therapeutic targets in acute myeloid leukemia.

Authors:  Jeffrey W Tyner; Denise K Walters; Stephanie G Willis; Mary Luttropp; Jason Oost; Marc Loriaux; Heidi Erickson; Amie S Corbin; Thomas O'Hare; Michael C Heinrich; Michael W Deininger; Brian J Druker
Journal:  Blood       Date:  2007-11-19       Impact factor: 22.113

Review 2.  Targeting signal transducer and activator of transcription signaling pathway in leukemias.

Authors:  Mustafa Benekli; Heinz Baumann; Meir Wetzler
Journal:  J Clin Oncol       Date:  2009-08-10       Impact factor: 44.544

Review 3.  The molecular details of cytokine signaling via the JAK/STAT pathway.

Authors:  Rhiannon Morris; Nadia J Kershaw; Jeffrey J Babon
Journal:  Protein Sci       Date:  2018-12       Impact factor: 6.725

Review 4.  STAT transcription factors in hematopoiesis and leukemogenesis: opportunities for therapeutic intervention.

Authors:  K A Dorritie; J A McCubrey; D E Johnson
Journal:  Leukemia       Date:  2013-06-25       Impact factor: 11.528

5.  Inhibition of protein phosphatase 2A induces serine/threonine phosphorylation, subcellular redistribution, and functional inhibition of STAT3.

Authors:  A Woetmann; M Nielsen; S T Christensen; J Brockdorff; K Kaltoft; A M Engel; S Skov; C Brender; C Geisler; A Svejgaard; J Rygaard; V Leick; N Odum
Journal:  Proc Natl Acad Sci U S A       Date:  1999-09-14       Impact factor: 11.205

6.  Dynamic trafficking of STAT5 depends on an unconventional nuclear localization signal.

Authors:  Ha Youn Shin; Nancy C Reich
Journal:  J Cell Sci       Date:  2013-05-23       Impact factor: 5.285

7.  A novel fusion of RBM6 to CSF1R in acute megakaryoblastic leukemia.

Authors:  Ting-lei Gu; Thomas Mercher; Jeffrey W Tyner; Valerie L Goss; Denise K Walters; Melanie G Cornejo; Cynthia Reeves; Lana Popova; Kimberly Lee; Michael C Heinrich; John Rush; Masanori Daibata; Isao Miyoshi; D Gary Gilliland; Brian J Druker; Roberto D Polakiewicz
Journal:  Blood       Date:  2007-03-14       Impact factor: 22.113

8.  The influence of STAT5 antisense oligonucleotides on the proliferation and apoptosis of selected human leukaemic cell lines.

Authors:  M Baśkiewicz-Masiuk; M Masiuk; B Machaliński
Journal:  Cell Prolif       Date:  2003-10       Impact factor: 6.831

9.  High-throughput sequence analysis of the tyrosine kinome in acute myeloid leukemia.

Authors:  Marc M Loriaux; Ross L Levine; Jeffrey W Tyner; Stefan Fröhling; Claudia Scholl; Eric P Stoffregen; Gerlinde Wernig; Heidi Erickson; Christopher A Eide; Roland Berger; Olivier A Bernard; James D Griffin; Richard M Stone; Benjamin Lee; Matthew Meyerson; Michael C Heinrich; Michael W Deininger; D Gary Gilliland; Brian J Druker
Journal:  Blood       Date:  2008-02-05       Impact factor: 22.113

10.  Comparative proteomics in acute myeloid leukemia.

Authors:  Magdalena Luczak; Maciej Kaźmierczak; Luiza Hadschuh; Krzysztof Lewandowski; Mieczysław Komarnicki; Marek Figlerowicz
Journal:  Contemp Oncol (Pozn)       Date:  2012-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.